Eliem Therapeutics Inc.

NASDAQ: ELYM · Real-Time Price · USD
5.11
-0.05 (-0.97%)
At close: Oct 02, 2024, 10:00 PM

Eliem Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a
Gross Profit
n/a n/a n/a n/a
Operating Income
-82.02M -21.47M -45.13M -35.67M
Interest Income
n/a n/a 1.2K 450.00
Pretax Income
-73.9M -35.12M -45.24M -47.48M
Net Income
-73.9M -35.12M -45.35M -47.48M
Selling & General & Admin
16.02M 9.89M 18.92M 12.35M
Research & Development
14.18M 15.41M 26.21M 23.32M
Other Expenses
51.82M n/a n/a n/a
Operating Expenses
82.02M 37.41M 45.13M 35.67M
Interest Expense
n/a n/a 1.59M n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
n/a 37.41M 45.13M 35.67M
Income Tax Expense
n/a -21.47K 109K -66.56K
Shares Outstanding (Basic)
48.16M 26.99M 26.31M 26.24M
Shares Outstanding (Diluted)
48.16M 26.99M 26.31M 26.24M
EPS (Basic)
-1.53 -1.3 -1.72 -1.81
EPS (Diluted)
-1.53 -1.3 -1.72 -1.81
EBITDA
-82.02M -13.65M -43.65M -35.5M
EBIT
n/a n/a -43.65M n/a
Depreciation & Amortization
n/a 21.47M 45.13M 35.67M